Biotech

All Articles

AN 2 halves headcount, stops phase 3 trial after records dissatisfy

.AN2 Therapies is actually rethinking its business in feedback to uninspired midphase records, swear...

Merck spends $700M for bispecific, spying autoimmune position and odds to test Amgen in cancer

.Merck &amp Co. is actually paying $700 thousand ahead of time to test Amgen in a blood cancer cells...

Gilead pays for J&ampJ $320M to go out licensing deal for seladelpar

.With Gilead Sciences about to an FDA decision for its own liver illness medication seladelpar, the ...

' All hands on deck' at Lilly as peers target obesity market

.CEO David Ricks can see the providers establishing outdoors tents at basecamp responsible for Eli L...

Entero laying off team, moving out of workplace and stopping briefly R&ampD

.Bed Liquidators has actually switched Entero Therapeutics white as a piece. The collector bought En...

Exelixis falls ADC after determining it is actually no match for Tivdak

.Exelixis is actually quiting on its own cells factor (TF)- targeting antibody-drug conjugate after ...

Relay loses interest in SHP2 inhibitor after Genentech leaves behind

.3 weeks after Roche's Genentech device ignored an SHP2 prevention treaty, Relay Rehab has actually ...

Stoke's Dravet syndrome med released of partial clinical hold

.Stoke Therapeutics' Dravet disorder medication has been freed from a predisposed grip, clearing the...

Fierce Biotech's Gabrielle Masson presents Intense 15 at NYSE

.Fierce Biotech Associate Publisher Gabrielle Masson showed the 2024 training class of Ferocious 15 ...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH prospect

.Novo Nordisk has axed its once-monthly twin GLP-1/ GIP receptor agonist, finishing (PDF) progressio...